Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee. 1981

A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke

We report the prognostic importance of strength of reaction to BCG, tumor histology and clinical factors in patients with previously untreated high-risk (Clark, III, IV and V) primary malignant melanoma. One hundred and one such patients receive high-dose BCG (1 x 10(8) viable units) by Heaf gun as an adjuvant to standardized primary surgery according to EORTC Protocol 18741. Univariate analysis of disease-free interval (DFI) indicates that the degree of maximum reaction to BCG (p = 0.0003), Breslow thickness (p = 0.0003) and Clark level (p = 0.002) are highly significant prognostic factors. When a multivariate model using Cox's proportional hazard regression was used for DFI, the degree of maximum reaction to BCG and Breslow thickness were by far the most significant criteria. A prognostic equation wa obtained to predict DFI from maximum BCG reaction and Breslow thickness. From analysis of the "scores" calculated in this way it appears that the two variables act independently. This technique permits the determination of values that are predictive of DFI and discriminate between subgroups of patients with different DFI characteristics (5 groups, p less than 0.0001). This exercise was repeated for survival and similar results were obtained. The degree of a patient's immune reaction to BCG administered therapeutically is of paramount importance in determining the likelihood of survival. This factor and the Breslow thickness can be integrated to produce a mathematical equation which accurately predicts survival for appropriately treated melanoma patients.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
August 1997, Melanoma research,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
June 2007, Archives of dermatology,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
August 2002, Seminars in oncology,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
April 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
March 1978, The Journal of the Kansas Medical Society,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
May 2024, Journal of cancer research and clinical oncology,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
June 1979, Biomedicine / [publiee pour l'A.A.I.C.I.G.],
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
January 1996, Dermatology (Basel, Switzerland),
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
August 2019, Melanoma research,
A J Cochran, and M E Buyse, and F J Lejeune, and E Macher, and J Revuz, and P Rümke
September 1987, Journal of surgical oncology,
Copied contents to your clipboard!